NASDAQ:TPST - Tempest Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.50
  • Forecasted Upside: 893.49 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.07
▼ -0.07 (-2.23%)

This chart shows the closing price for TPST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tempest Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TPST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TPST

Analyst Price Target is $30.50
▲ +893.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $30.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 893.49% upside from the last price of $3.07.

This chart shows the closing price for TPST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Tempest Therapeutics. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Piper SandlerLower Price Target$20.00 ➝ $10.00Low
5/13/2022HC WainwrightLower Price Target$51.00 ➝ $35.00Low
10/21/2021William BlairInitiated CoverageOutperformMedium
8/13/2021HC WainwrightReiterated RatingBuy$51.00Low
7/13/2021HC WainwrightInitiated CoverageBuyHigh
7/6/2021Piper SandlerInitiated CoverageOverweight$23.00High
1/6/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$75.00 ➝ $30.00N/A
1/6/2021LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
8/12/2020WedbushReiterated RatingHold$45.00Low
6/14/2020SVB LeerinkReiterated RatingOutperform$75.00Medium
6/14/2020Roth CapitalReiterated RatingBuy$90.00Medium
5/29/2020CitigroupInitiated CoverageBuy$90.00High
5/21/2020OppenheimerReiterated RatingHold$30.00High
4/19/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
4/7/2020Roth CapitalLower Price Target$525.00 ➝ $90.00Medium
4/6/2020OppenheimerDowngradeOutperform ➝ Market Perform$375.00 ➝ $30.00High
4/6/2020WedbushDowngradeOutperform ➝ Neutral$375.00 ➝ $60.00High
3/24/2020CitigroupLower Price TargetBuy$345.00 ➝ $300.00Low
2/7/2020CitigroupInitiated CoverageBuy$345.00High
1/20/2020SVB LeerinkReiterated RatingOutperformMedium
1/10/2020Roth CapitalInitiated CoverageBuy$525.00High
9/16/2019Jefferies Financial GroupReiterated RatingBuy$330.00High
8/15/2019WedbushReiterated RatingBuy$360.00Low
8/13/2019OppenheimerLower Price TargetOutperform$390.00 ➝ $375.00Low
7/18/2019WedbushInitiated CoverageOutperform$360.00Low
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$390.00Medium
7/16/2019OppenheimerInitiated CoverageOutperform$390.00 ➝ $390.00High
7/15/2019CitigroupInitiated CoverageOutperform$390.00High
3/13/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$330.00High
1/4/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$435.00N/A
12/13/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$360.00N/A
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/21/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/19/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Tempest Therapeutics logo
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.07
Low: $2.96
High: $3.14

50 Day Range

MA: $3.14
Low: $2.27
High: $4.15

52 Week Range

Now: $3.07
Low: $2.16
High: $41.00

Volume

28,681 shs

Average Volume

209,446 shs

Market Capitalization

$22.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Tempest Therapeutics?

The following sell-side analysts have issued reports on Tempest Therapeutics in the last year: HC Wainwright, Piper Sandler, William Blair, and Zacks Investment Research.
View the latest analyst ratings for TPST.

What is the current price target for Tempest Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Tempest Therapeutics in the last year. Their average twelve-month price target is $30.50, suggesting a possible upside of 893.5%.
View the latest price targets for TPST.

What is the current consensus analyst rating for Tempest Therapeutics?

Tempest Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TPST will outperform the market and that investors should add to their positions of Tempest Therapeutics.
View the latest ratings for TPST.

How do I contact Tempest Therapeutics' investor relations team?

Tempest Therapeutics' physical mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company's listed phone number is (415) 798-8589 and its investor relations email address is [email protected] The official website for Tempest Therapeutics is www.millendo.com. Learn More about contacing Tempest Therapeutics investor relations.